2016 年第 5 期 第 14 卷

利妥昔单抗联合CHOP方案治疗B细胞非霍奇金淋巴瘤的临床疗效

作者：

单位：

关键词：利妥昔单抗，非霍奇金淋巴瘤，CHOP方案

• 摘要：
• 【摘要】摘要：目的：探讨利妥昔单抗联合CHOP方案治疗B细胞型非霍奇金淋巴瘤的临床效果和不良反应。方法：选择96例CD20阳性的B细胞型非霍奇金淋巴瘤分为研究组和对照组，研究组采用利妥昔单抗与CHOP方案联合治疗，对照组只采用CHOP化疗方案。应用4个疗程后评价两组疗效及不良反应。结果：研究组治疗有效率为90.0%，高于对照组的72.3%，差异有统计学意义（P<0.05）。而且两组的白细胞下降、脱发、恶心呕吐、便秘、血小板减少、贫血、肺部感染等不良反应差异对比无统计学意义（P>0.05）。研究组1年、3年、5年无进展生存率（PFS）为81.6%、61.2%、26.5%，总生存率（OS）为89.8%、65.3%、30.6%，均明显高于对照组，差异均具有统计学意义（P＜0.05）。结论：采用利妥昔单抗与CHOP 方案联合治疗B细胞型非霍奇金淋巴瘤，可以提高临床疗效和远期生存，且不因联合化疗而增加不良反应。
• Abstract: Objective: To investigate the clinical effects and adverse reactions of rituximab combined with CHOP regimen in the treatment of non Hodgkin's lymphoma of B cell type. Methods: 96 cases of CD20 positive B cell type non Hodgkin lymphoma were divided into study group and control group. The study group was treated with rituximab and CHOP regimen, and the control group was treated with CHOP chemotherapy only. The efficacy and adverse reactions of the two groups were evaluated after 4 courses of treatment. Results: the effective rate of the study group was 90%, higher than that of the control group (72.34%), the difference was statistically significant (P<0.05). And the two groups of white blood cells, hair loss, nausea and vomiting, constipation, thrombocytopenia, anemia, pulmonary infection and other adverse reaction rates were not statistically significant difference (P>0.05). The research group on the 1 year, 3 years, 5 years, progression free survival (PFS) was 81.6% and 61.2%, 26.5%, rate of overall survival (OS) was 89.8%, 65.3%, 30.6%) were significantly higher than those in control group compared with statistical significance in two groups at 1, 3, and 5 years of PFS and OS, the difference is significant (P < 0.05). Conclusion: the combination of rituximab and CHOP regimen in the treatment of B cell non Hodgkin's lymphoma can improve the clinical efficacy and long-term survival, and not increase the adverse reaction due to combination chemotherapy.